The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.
 
Dai Okemoto
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); Daiichi Sankyo/UCB Japan (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Yuto Kubo
No Relationships to Disclose
 
Kazuma Sato
No Relationships to Disclose
 
Masaki Nakamura
Honoraria - AstraZeneca; Illumina
Research Funding - Illumina
 
Shingo Sakashita
No Relationships to Disclose
 
Saori Mishima
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Takashi Kojima
Honoraria - BeiGene Japan; Bristol-Myers Squibb; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; TFBS Bioscience, Inc.
Consulting or Advisory Role - BeiGene Japan; Boehringer Ingelheim; Nippon Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Taiho Pharmaceutical (Inst)
 
Takeo Fujita
No Relationships to Disclose